News from protagonist therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 01, 2022, 16:05 ET Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President, and Chief...

May 26, 2022, 17:00 ET Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with...

May 04, 2022, 16:05 ET Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update

Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus Presented...

Apr 25, 2022, 16:25 ET Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological...

Apr 19, 2022, 16:15 ET Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 18, 2022, it issued inducement awards to three recently hired employees in ...

Mar 28, 2022, 07:06 ET Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer

Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of Asif Ali as Executive Vice President and Chief Financial Officer (CFO). In ...

Mar 16, 2022, 07:00 ET Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today earning a $25 million milestone payment from its...

Feb 28, 2022, 16:05 ET Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended...

Feb 10, 2022, 07:00 ET Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive...

Jan 04, 2022, 12:24 ET Protagonist Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive...

Dec 12, 2021, 09:30 ET Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating...

Dec 03, 2021, 07:00 ET Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief...

Dec 02, 2021, 16:05 ET Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final...

Nov 15, 2021, 07:00 ET Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced results from a Phase 2a study in which rusfertide, an...

Nov 11, 2021, 07:00 ET Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief...

Nov 04, 2021, 07:00 ET Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that two abstracts highlighting updated data from its...

Nov 03, 2021, 16:05 ET Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the third quarter ended...

Oct 26, 2021, 07:00 ET Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that it will receive a $7.5 million milestone payment...

Oct 12, 2021, 07:00 ET Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief...

Oct 11, 2021, 07:00 ET Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has...

Oct 04, 2021, 07:00 ET Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its...

Sep 17, 2021, 07:00 ET Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S....

Sep 15, 2021, 17:05 ET Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on September 15, 2021, it issued inducement awards to two recently hired employees...

Sep 07, 2021, 07:00 ET Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the appointment of Scott Plevy, M.D., to the role of...

Aug 10, 2021, 08:05 ET Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute...